Evidence map›Paper›PMID 41126833›Full record

ReviewFrontiers in immunology2025

The innate immune response in SARS-CoV2 infection: focus on toll-like receptor 4 in severe disease outcomes.

Enrico Maggi, Nadine Landolina, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca, Bruno Azzarone, Lorenzo Moretta

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Enrico MaggiTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Nadine LandolinaTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Francesca Romana MariottiTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Enrico MunariDepartment of Pathology and Diagnostics, University and Hospital Trust Verona, Verona, Italy.
Nicola TuminoInnate Lymphoid Cells Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola VaccaInnate Lymphoid Cells Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Bruno AzzaroneTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lorenzo MorettaTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innate immunity is the first line of defense against infections, including the detection and response to SARS-CoV-2. Cells of the innate system are usually activated within hours after pathogen exposure and do not generate conventional immunological memory. In this review, the current knowledge of the innate immune cells and of pattern-recognition receptors in sensing and responding to SARS-CoV-2 to mount a protective response has been shortly reviewed. Subsequently, the evasion strategies of the virus, as the inhibition of IFN-I/III production and autophagic response, counteracting the innate cell activity (including NK cells), have been briefly outlined. In the course of the infection, these strategies are also capable of rendering dysfunctional most innate cells, thus deeply interfering with the onset and maintenance of adaptive immunity. Possible mechanism(s) for the maintenance of dysfunctional innate immune response are also discussed. In this context, the importance of a rapid and robust activation of innate immunity through toll-like receptor (TLR) 4 as a key paradigm central to host defense against COVID-19 pathogenesis is also illustrated. We also discuss how the viral excess plus inflammatory signals upregulating TLR4 on innate cells may initiate a vicious loop which maintains and improves hyperinflammation, leading to the most critical outcomes. Targeting the TLR4 or its signaling pathway may be a promising therapeutic strategy, offering the dual benefits of viral suppression and decreasing inflammation.

Indexed as

COVID-19Immunity, InnateSARS-CoV-2Toll-Like Receptor 4AnimalsHumansKiller Cells, NaturalSignal TransductionTLR4 protein, humanToll-Like Receptor 4innate immunityNK cellsSARS-CoV2 infectionspike glycoproteinTLR4

Identifiers

PMID41126833
PMCPMC12537681

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.